Literature DB >> 26725899

Universal screening for chronic hepatitis C virus.

Mitchell L Shiffman1.   

Abstract

Chronic hepatitis C virus (HCV) infection affects an estimated 123 million persons worldwide and is the leading cause of cirrhosis and hepatocellular carcinoma in most countries. Approximately 75% of persons with chronic HCV were born between the years 1945-1965 and screening of patients in this birth cohort is now advocated. Unfortunately, these recommendations are not readily applied and a sizable population of infected persons who could benefit from treatment fall outside the birth cohort. Universal screening for HCV would be optimal. However, the primary limitation once patients are identified is accessing treatment which remains restricted in most countries.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis C virus; risk factors; sustained virological response; universal screening

Mesh:

Substances:

Year:  2016        PMID: 26725899     DOI: 10.1111/liv.13012

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics.

Authors:  Newaz Hossain; Bharat Puchakayala; Pushpjeet Kanwar; Siddharth Verma; George Abraham; Zhanna Ivanov; Muhammad Obaid Niaz; Smruti R Mohanty
Journal:  Dig Dis Sci       Date:  2017-09-14       Impact factor: 3.199

2.  A Qualitative Study of Implementing Universal Hepatitis C Screening Among Adults at an Urban Community-Based Health Provider in Delaware.

Authors:  Rini Jose; Deborah Kahal; Karla Testa; Neal D Goldstein
Journal:  Dela J Public Health       Date:  2021-07-15

Review 3.  State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization.

Authors:  Cecilia Trucchi; Andrea Orsi; Cristiano Alicino; Laura Sticchi; Giancarlo Icardi; Filippo Ansaldi
Journal:  J Immunol Res       Date:  2016-10-24       Impact factor: 4.818

4.  Optimization of hepatitis C virus screening strategies by birth cohort in Italy.

Authors:  Loreta A Kondili; Ivane Gamkrelidze; Sarah Blach; Andrea Marcellusi; Massimo Galli; Salvatore Petta; Massimo Puoti; Stefano Vella; Homie Razavi; Antonio Craxi; Francesco S Mennini
Journal:  Liver Int       Date:  2020-04-02       Impact factor: 5.828

5.  Screening for Hepatitis C Virus: How Universal Is Universal?

Authors:  Ravi Jhaveri
Journal:  Clin Ther       Date:  2020-07-23       Impact factor: 3.393

6.  Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings.

Authors:  Carmen N Burrell; Melinda J Sharon; Stephen M Davis; Elena M Wojcik; Ian B K Martin
Journal:  West J Emerg Med       Date:  2018-10-09

7.  Population health challenges in primary care: What are the unfinished tasks and who should do them?

Authors:  Frederick North; Sidna M Tulledge-Scheitel; John C Matulis; Jennifer L Pecina; Andrew M Franqueira; Sarah S Johnson; Rajeev Chaudhry
Journal:  SAGE Open Med       Date:  2018-09-17

8.  Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Authors:  Loreta A Kondili; Sarah Robbins; Sarah Blach; Ivane Gamkrelidze; Anna L Zignego; Maurizia R Brunetto; Giovanni Raimondo; Gloria Taliani; Andrea Iannone; Francesco P Russo; Teresa A Santantonio; Massimo Zuin; Luchino Chessa; Pierluigi Blanc; Massimo Puoti; Maria Vinci; Elke M Erne; Mario Strazzabosco; Marco Massari; Pietro Lampertico; Maria G Rumi; Alessandro Federico; Alessandra Orlandini; Alessia Ciancio; Guglielmo Borgia; Pietro Andreone; Nicola Caporaso; Marcello Persico; Donatella Ieluzzi; Salvatore Madonia; Andrea Gori; Antonio Gasbarrini; Carmine Coppola; Giuseppina Brancaccio; Angelo Andriulli; Maria G Quaranta; Simona Montilla; Homie Razavi; Mario Melazzini; Stefano Vella; Antonio Craxì
Journal:  Liver Int       Date:  2018-08-10       Impact factor: 5.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.